MYH9 表达在切除的非小细胞肺癌中的预后意义。
Prognostic significance of MYH9 expression in resected non-small cell lung cancer.
机构信息
Department of Respiratory Medicine, School of Medicine, Kitasato University, Kanagawa, Japan.
Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.
出版信息
PLoS One. 2015 Mar 31;10(3):e0121460. doi: 10.1371/journal.pone.0121460. eCollection 2015.
INTRODUCTION
Myosin-9 (MYH9) belongs to the myosin superfamily of actin-binding motor protein. Recently, MYH9 has been thought to be associated with cancer cell migration, invasion, and metastasis. The aims of this study were to immunohistochemically examine MYH9 expression in surgically resected non-small cell lung cancer (NSCLC), and evaluate its correlations with clinicopathological parameters and the prognosis of patients.
METHODS
MYH9 expression was immunohistochemically studied in 266 consecutive resected NSCLCs, and its associations with clinicopathological parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of MYH9 expression on survival.
RESULTS
MYH9 expression was detected in 102 of 266 (38.3%) NSCLCs. MYH9 expression was significantly correlated with the adenocarcinoma histology (P = 0.014), poorer differentiation ((P = 0.033), intratumoral vascular invasion and lymphatic invasion ((P = 0.013 and P = 0.045 respectively), and a poorer prognosis ((P = 0.032). In addition, multivariable analysis revealed that MYH9 expression independently predicted a poorer survival (HR, 2.15; 95%CI, 1.17-3.92; (P = 0.01).
CONCLUSION
The present study revealed that MYH9 is expressed in a subset of NSCLC with a more malignant nature, and its expression is an indicator of a poorer survival probability.
简介
肌球蛋白-9（MYH9）属于肌球蛋白超家族的肌动蛋白结合马达蛋白。最近，MYH9 被认为与癌细胞迁移、侵袭和转移有关。本研究的目的是免疫组织化学检测手术切除的非小细胞肺癌（NSCLC）中 MYH9 的表达，并评估其与临床病理参数和患者预后的相关性。
方法
对 266 例连续切除的 NSCLC 进行 MYH9 表达的免疫组织化学研究，并评估其与临床病理参数的相关性。Kaplan-Meier 生存分析和 Cox 比例风险模型用于估计 MYH9 表达对生存的影响。
结果
在 266 例 NSCLC 中，有 102 例（38.3%）检测到 MYH9 表达。MYH9 表达与腺癌组织学（P = 0.014）、较差的分化（P = 0.033）、肿瘤内血管浸润和淋巴管浸润（P = 0.013 和 P = 0.045）显著相关，以及预后较差（P = 0.032）。此外，多变量分析显示，MYH9 表达独立预测生存较差（HR，2.15；95%CI，1.17-3.92；P = 0.01）。
结论
本研究表明，MYH9 在具有更恶性特征的 NSCLC 亚组中表达，其表达是生存概率较差的指标。
Zotero 插件